ArticleBMC cancer2026
The effects of certification of head and neck cancer centers on the survival of patients with a head and neck cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHead and neck cancers represent a heterogeneous group of tumor in terms of both, their entity and location. This includes cancers of the lip, oral cavitiy, pharynx (epi-, oro- and hypopharynx), larynx, nasal cavity/ sinus and salivary gland. Additionally, they are associated with functional impairments that place highly specific demands on treating practitioners. Since the introduction of the German National Cancer Plan in 2008, cancer treatment has been aligned with the latest scientific findings through evidence-based guidelines. Meanwhile, treatment courses and outcomes have been systematically recorded by expanding the German cancer registry. In addition, the certification of treatment centers aims to ensure consistently high-quality care. Given the considerable investment of time, personnel, and financial resources required for certification, the question arises whether patients with head and neck cancer benefit from receiving (initial) treatment at a certified center compared to a non-certified facility.
methodsWe used patient-specific information from statutory health insurance (SHI) and clinical cancer registry (CCR) data for the period 2009–2017 as well as hospital characteristics from standardized quality reports. We applied multivariable Cox regressions to analyze differences in survival between patients treated in hospitals with and without German Cancer Society (DKG) certification.
resultsThe sample comprised 52,749 (SHI) and 15,287 (CCR) patients with head and neck cancer who were treated in 872 hospitals (44 DKG-certified, 828 not DKG-certified). 15.5% (SHI) and 25.9% (CCR) of patients were (initially) treated in DKG-certified cancer centers. Cox regression analysis for overall survival showed that patients treated in DKG-certified cancer centers were at significantly lower risk of death (SHI data: HR = 0.94, 95% CI = 0.89–1.00, p = 0.043; CCR data: HR = 0.89, 95% CI = 0.83–0.95, p < 0.001). Notably, the difference was even more pronounced for recurrence-free survival (CCR data: HR = 0.81, 95% CI = 0.72–0.92, p = 0.001).
conclusionAlthough achieving certification requires a substantial investment of personnel, time, and financial resources by the treating institution, it is associated with a measurable survival advantage for patients. Therefore, treatment of head and neck cancer patients should preferably be provided at certified head and neck cancer centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.